TipRanks
Advertisement
Advertisement

DE:8F8 Stock Latest News

SynAct Pharma Launches Global Investor and Partnering Push
Company AnnouncementsSynAct Pharma Launches Global Investor and Partnering Push
12d ago
WHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate
PremiumCompany Announcements
WHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate
17d ago
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
PremiumCompany Announcements
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
26d ago
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
PremiumCompany Announcements
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
1M ago
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
PremiumCompany Announcements
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
1M ago
SynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D
PremiumCompany AnnouncementsSynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D
1M ago
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
Premium
Company Announcements
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
2M ago
SynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation
Premium
Company Announcements
SynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation
2M ago
SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
PremiumCompany Announcements
SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
3M ago
SynAct preclinical data point to osteoarthritis potential for resomelagon
PremiumCompany Announcements
SynAct preclinical data point to osteoarthritis potential for resomelagon
3M ago
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
PremiumCompany Announcements
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
3M ago
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
PremiumCompany Announcements
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
4M ago
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
PremiumCompany AnnouncementsSynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
4M ago
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
Premium
Company Announcements
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
4M ago
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
Premium
Company Announcements
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
4M ago
8F8
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
PremiumCompany Announcements
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
4M ago
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
PremiumCompany Announcements
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
4M ago
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
PremiumCompany Announcements
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
4M ago
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
PremiumCompany Announcements
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
5M ago
SynAct Pharma convenes AGM and opts to retain earnings
PremiumCompany AnnouncementsSynAct Pharma convenes AGM and opts to retain earnings
5M ago
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
Premium
Company Announcements
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
5M ago
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
Premium
Company Announcements
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >